[Parenteral iron therapy in chronic kidney disease or chronic heart failure]

Area of Science:

• Nephrology
• Cardiology
• Hematology

Background:

• Iron deficiency and anemia are prevalent in chronic kidney disease (CKD) and chronic heart failure (CHF).
• These conditions are linked to reduced quality of life and increased mortality.
• Current anemia treatments with erythropoietic growth factors show limited efficacy.

Purpose of the Study:

• To investigate the role of iron deficiency in CKD and CHF.
• To evaluate the effectiveness of parenteral iron therapy in managing iron deficiency symptoms.

Main Methods:

• Review of existing literature on iron metabolism in CKD and CHF.
• Analysis of the impact of chronic inflammation on iron regulation via hepcidin.
• Assessment of parenteral iron therapy's effects on CHF symptoms.

Main Results:

• Chronic inflammation in CKD elevates hepcidin, hindering iron absorption and utilization.
• Both absolute and functional iron deficiency occur, with ferritin levels not always indicative of tissue iron status.
• Parenteral iron therapy alleviates iron deficiency symptoms in CHF patients, independent of hemoglobin changes.

Conclusions:

• Iron deficiency is a significant issue in CKD and CHF, requiring focused management.
• Parenteral iron is beneficial for CHF symptoms, but long-term outcomes require further study.
• Understanding iron dysregulation, particularly hepcidin's role, is crucial for effective treatment strategies.